UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30~~March 31, ~~2025~~2026

Oror

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ~~______~~ to ~~______~~

Commission file number 333-143630

~~BYRN~~BRYN INC. (Exact name of registrant as specified in its charter)

Nevada

20-4682058

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

50 West Liberty Street, Suite 880
2332 Galiano St., 2d Floor, #5138
Reno, Nevada		89501
Coral Gables, Florida		33143
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (~~646~~305) ~~768~~988-~~8417~~9807

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☐ Yes ☒ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☐ Yes ☒ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.) Yes ☒ No ☐

As of ~~October~~May 2119, ~~2025~~2026 the Registrant had ~~419~~450,~~984~~000,~~423~~ 000 shares of Common Stock issued and outstanding.

~~BYRN~~BRYN INC.

QUARTERLY REPORT ON FORM 10-Q

For the ~~Nine~~Three Months Ended ~~September~~March 3031, ~~2025~~ 2026 and ~~2024~~2025

Part I – FINANCIAL INFORMATION		1

Item 1.	Financial Statements (unaudited)	2

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	12

Item 4.	Controls and Procedures	12

Part II – OTHER INFORMATION		14

Item 1.	Legal Proceedings	14

Item 1A.	Risk Factors	14

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	14

Item 3.	Defaults Upon Senior Securities	14

Item 4.	Mine Safety Disclosures	14

Item 5.	Other Information	14

Item 6.	Exhibits	15

SIGNATURES		16

PART I – FINANCIAL INFORMATION

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Information contained in this quarterly report on Form 10-Q contains “forward-looking statements.” These forward-looking statements are contained principally in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend” or “project” or the negative of these words or other variations on these words or comparable terminology. The forward-looking statements herein represent our expectations, beliefs, plans, intentions or strategies concerning future events, including, but not limited to: our ability to ~~consummate~~implement ~~the~~our ~~Merger,~~business ~~as such term is defined below~~plan; our future financial performance; the continuation of historical trends; the sufficiency of our resources in funding our operations; ~~our intention to engage in mergers~~ and ~~acquisitions; and~~ our liquidity and capital needs. Our forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. Moreover, our forward-looking statements are subject to various known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by any forward-looking statements. These risks, uncertainties and other factors include but are not limited to: the risks of limited management, labor, and financial resources; our ability to establish and maintain adequate internal controls; our ability to develop and maintain a market in our securities; and our ability to obtain financing, if and when needed, on terms that are acceptable. Except as required by applicable laws, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available ~~or other events occur in the future~~.

As used in this quarterly report on Form 10-Q, “we”, “our”, “us” and the “Company” refer to ~~Byrn~~Bryn Inc. a Nevada corporation unless the context requires otherwise.

Item 1. Financial Statements.

Index to Financial Statements

		Page
FINANCIAL STATEMENTS:
Balance Sheets, September 30, 2025 (unaudited), and December 31, 2024		3
Balance Sheets, March 31, 2026 (unaudited), and December 31, 2025		3
Unaudited Statements of Operations for the Three and Nine Months Ended September 30, 2025, and 2024		4
Unaudited Statements of Operations for the Three Months Ended March 31, 2026, and 2025		4
Unaudited Statements of Changes in Stockholders’ Deficit for the Three and Nine Months Ended September 30, 2025, and 2024		5
Unaudited Statements of Changes in Stockholders’ Deficit for the Three Months Ended March 31, 2026, and 2025		5
Unaudited Statements of Cash Flows for the Nine Months Ended September 30, 2025, and 2024		6
Unaudited Statements of Cash Flows for the Three Months Ended March 31, 2026, and 2025		6
Notes to the Unaudited Interim Financial Statements		7

~~BYRN~~BRYN INC.

BALANCE SHEETS

	September 30,			December 31,
	March 31,			December 31,
	2025			2024
	2026			2025
	(Unaudited)
ASSETS
Total Assets	$	-		$	-
Prepaid expenses	$	1,073		$	-
Accounts receivable other		1,105			-
Current assets		2,178			-
Total Assets	$	2,178		$	-
LIABILITIES & STOCKHOLDERS’ DEFICIT
Accounts payable	$	216,~~533~~221		$	137,~~352~~577
Related party payables		8220,~~635~~219			4389,~~234~~035
Current liabilities		8536,~~168~~440			5696,~~586~~612
Total liabilities		8536,~~168~~440			5696,~~586~~612
Stockholders’ Deficit
Preferred stock, par value $0.001, 10,000,000 shares authorized, 10,000,000 shares issued and outstanding as of September 30, 2025, and December 31, 2024, respectively		10,000			10,000
Preferred stock, par value $0.001, 10,000,000 shares authorized, 10,000,000 issued and outstanding as of March 31, 2026 and December 31, 2025 respectively		10,000			10,000
Common stock, par value $0.001, 500,000,000 shares authorized, 419,984,423 shares issued and outstanding of shares as of September 30, 2025, and December 31, 2024		419,985			419,985
Common stock, par value $0.001, 500,000,000 shares authorized, 450,000,000 issued and outstanding shares as of March 31, 2026 and 419,984,423 issued and outstanding as of December 31, 2025		450,000			419,985
Additional paid in capital		117,~~035~~098,~~540~~810			117,035,540
Accumulated deficit		(117,~~550~~593,~~693~~073	)		(117,~~522~~562,~~111~~137	)
Total Stockholders’ (Deficit)		(8534,~~168~~263	)		(5696,~~586~~612	)
Total Liabilities and Stockholders’ Deficit	$	-2,177		$	-0

The accompanying notes are an integral part of these unaudited financial statements.

~~BYRN~~ BRYN INC. ~~STATEMENTS OF OPERATIONS (Unaudited)~~

	Three months Ended September 30, 2025			Three months Ended September 30, 2024			Nine months Ended September 30, 2025			Nine months Ended September 30, 2024
Revenue	$	-		$	-		$	-		$	-
Operating Expenses:
Administrative expenses -related party		3,700			21,796			28,582			25,905
Total operating expenses		3,700			21,796			28,582			25,905
Loss from operations		(3,700	)		(21,796	)		(28,582	)		(25,905	)
Other (expense) net		-			-			-			-
Loss before provision for income taxes		(3,700	)		(21,796	)		(28,582	)		(25,905	)
Provision for income taxes		-			-			-			-
Net Loss	$	(3,700	)	$	(21,796	)	$	(28,582	)	$	(25,905	)
Basic and diluted (loss) per common share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
Weighted average number of shares outstanding		419,984,423			419,984,423			419,984,423			419,984,423

STATEMENTS OF OPERATIONS

~~The accompanying notes are an integral part of these unaudited financial statements.~~(Unaudited)

	Three Months			Three Months
	Ended			Ended
	March 31,			March 31,
	2026			2025

Operating Expenses:
Administrative expenses		30,937			16,410
Total operating expenses		30,937			16,410
(Loss) from operations		(30,937	)		(16,410	)
Other (expense) net		-			-
Income (loss) before provision for income taxes		(30,937	)		(16,410	)
Provision for income taxes		-			-
Net Loss		(30,937	)		(16,410	)

Basic and diluted (loss) per common share	$	(0.00	)	$	(0.00	)

Weighted average number of shares outstanding		450,000,000			419,763,612

~~BYRN~~The ~~INC.~~accompanying ~~STATEMENTS~~notes OFare ~~CHANGES~~an INintegral ~~STOCKHOLDERS’~~part ~~DEFICIT (Unaudited)~~of these unaudited financial statements.

									Additional					Total
	Preferred Stock				Common Stock				Paid-in		Accumulated			Stockholders’
	Shares		Value		Shares		Value		Capital		Deficit			Deficit
Balance, December 31, 2023		10,000,000	$	10,000		419,984,423	$	419,985	$	117,017,022	$	(117,477,124	)	$	(30,117	)
Net loss												(1,817	)		(1,817	)
Balance, March 31, 2024		10,000,000	$	10,000		419,984,423	$	419,985	$	117,017,022	$	(117,478,941	)	$	(31,934	)
Net loss												(2,293	)		(2,293	)
Balance, June 30, 2024		10,000,000		10,000		419,984,423	$	419,985	$	117,017,022	$	(117,481,233	)	$	(34,227	)
Retirement of related party debt										18,518					18,518
Net loss												(21,796	)		(21,796	)
Balance, September 30, 2024		10,000,000		10,000		419,984,423	$	419,985	$	117,035,540	$	(117,503,029	)	$	(37,505	)

	Preferred Stock				Common Stock				Paid-in		Accumulated			Stockholders’
	Shares		Value		Shares		Value		Capital		Deficit			Deficit
Balance, December 31, 2024		10,000,000	$	10,000		419,984,423	$	419,985	$	117,035,540	$	(117,522,111	)	$	(56,586	)
Net loss												(16,410	)		(16,410	)
Balance, March 31, 2025		10,000,000	$	10,000		419,984,423	$	419,985	$	117,035,540	$	(117,538,521	)	$	(72,996	)
Net loss												(8,472	)		(8,472	)
Balance, June 30, 2025		10,000,000	$	10,000		419,984,423	$	419,985	$	117,035,540	$	(117,546,993	)	$	(81,468	)
Net loss												(3,700	)		(3,700	)
Balance, September 30, 2025		10,000,000	$	10,000		419,984,423	$	419,985	$	117,035,540	$	(117,550,693	)	$	(85,168	)

BRYN, INC.

~~The~~STATEMENTS OF ~~accompanying~~CHANGES ~~notes~~IN ~~are~~STOCKHOLDERS’ ~~an integral part of these unaudited financial statements.~~DEFICIT

5(Unaudited)

BYRN INC. STATEMENTS OF CASH FLOWS (Unaudited)

									Additional					Total
	Preferred Stock				Common Stock				Paid-in		Accumulated			Stockholders’
	Shares		Value		Shares		Value		Capital		Deficit			Deficit
Balance, December 31, 2024		10,000,000	$	10,000		419,984,423	$	419,985	$	117,035,540	$	(117,522,111	)	$	(56,586	)

Net loss												(16,410	)		(16,410	)

Balance, March 31, 2025		10,000,000	$	10,000		419,984,423	$	419,985	$	117,035,540	$	(117,538,521	)	$	(72,996	)

	Nine months			Nine months
	Preferred Stock						Common Stock				Paid-in		Accumulated			Stockholders’
	Ended			Ended
	Shares			Value			Shares		Value		Capital		Deficit			Deficit
	September 30,			September 30,
Balance, December 31, 2025		10,000,000		$	10,000			419,984,423	$	419,985	$	117,035,540	$	(117,562,137	)	$	(96,612	)
	2025			2024
Issuance of common shares to reduce related party debt								30,015,577		30,016		63,269					93,285
Cash Flows From Operating Activities:
Net loss														(30,937	)		(30,937	)
Net loss	$	(28,582	)	$	(25,905	)
Balance, March 31, 2026		10,000,000		$	10,000			450,000,000	$	450,000	$	117,098,810	$	(117,593,073	)	$	(34,263	)
Changes in operating assets and liabilities:
Accounts payable and accrued expenses		(10,819	)		(4,570	)
Net cash (used in) operating activities		(39,400	)		(30,475	)
Cash Flows From Financing Activities:
Proceeds from related party loans		39,400			30,475
Net cash provided by financing activities		39,400			30,475
Net Increase (Decrease) In Cash		-			-
Cash At The Beginning Of The Period		-			-
Cash At The End Of The Period	$	-		$	-

The accompanying notes are an integral part of these unaudited financial statements

~~BYRN~~ BRYN INC.

~~NOTES~~STATEMENTS OF TOCASH ~~FINANCIAL STATEMENTS~~FLOWS

~~FOR THE THREE AND NINE MONTHS ENDED~~(Unaudited)

SEPTEMBER 30, 2025 AND SEPTEMBER 30, 2024

	Three Months			Three Months
	Ended			Ended
	March 31,			March 31,
	2026			2025
Cash Flows From Operating Activities:
Net (loss)	$	(30,937	)	$	(16,410	)
Changes in operating assets and liabilities:
Prepaid expenses		(1,073	)		-
Accounts receivable other		(1,105	)		-
Accounts payable and accrued expenses		8,644			1,113
Net cash (used in) operating activities		(24,470	)		(15,297	)

Cash Flows From Investing Activities:
Net cash provided by (used in) investing activities		-			-

Cash Flows From Financing Activities:
Proceeds from related party loans		24,470			15,297
Net cash provided by financing activities		24,470			15,297

Net Increase (Decrease) In Cash		-			-
Cash At The Beginning Of The Period		-			-
Cash At The End Of The Period	$	-		$	-

Supplemental disclosure of non-cash investing and financing activities:
Common stock issued to reduce related party debt	$	93,285		$	-

~~NOTE~~The accompanying 1notes –are ~~ORGANIZATION~~an ~~AND~~integral ~~DESCRIPTION OF~~part ~~BUSINESS~~of these unaudited financial statements.

Byrn Inc. f/k/a “Byrn, Inc. (“Byrn”, “we”, “us”, or, the “Company”), is a Nevada corporation, formed in April 2011 to become an emerging healthcare knowledge solution company created to transform health and healthcare by developing the standard in measuring clinical performance and outcomes. The Company developed medical software with tools and analytics intended to reduce costs while improving clinical performance, outcomes, predictive insight, and evidence-based best clinical processes.6

OnBRYN August 10, 2011, holders of a majority of the Registrant’s outstanding Common Stock voted to amend the Registrant’s Articles of Incorporation to increase the number of its authorized shares of capital stock from 900,000,000 shares to 2,510,000,000 par value $0INC.~~001 shares (the “Amendment”) of which (a) 2,500,000,000 shares were designated as Common Stock and (b) 10,000,000 shares were designated as blank check preferred stock.~~

~~During the period from March 22, 2013, through~~NOTES ~~December~~TO ~~26,~~FINANCIAL ~~2019, the Company was dormant.~~STATEMENTS

~~On December 27, 2019, Custodian Ventures, LLC,~~FOR anTHE ~~entity~~THREE ~~controlled~~MONTHS by David Lazar, was appointed by the Nevada Court as the custodian of Byrn. On December 31, 2019, Mr. Lazar became the only Director and Officer of the Company also acting as its President, Treasurer, and Secretary.ENDED

~~On April 5, 2020, the Company granted Mr. Lazar~~MARCH 1031,~~000,000~~ ~~preferred~~2026 ~~shares~~AND ~~with~~MARCH ~~super-voting rights of 21~~31,~~000,000,000~~ ~~common shares.~~2025

~~On September 10, 2020, the Company filed a Certificate~~NOTE ~~of Designation with the State of Nevada changing the conversion and voting rights of the Company’s Series A preferred stock, $.001 par value per share to 250 for each one (~~1) ~~share~~– ofORGANIZATION ~~Series~~AND ADESCRIPTION ~~preferred~~OF ~~stock.~~BUSINESS

OnBryn ~~September~~Inc. ~~23,~~f/k/a ~~2020~~“Byrn, asInc. ~~a result of a private transaction~~(“Bryn”, 10“we”,~~000~~ “us”,~~000~~ ~~shares of Series A Convertible Preferred Stock~~or, ~~$0.001 par value per share (~~the “~~Shares~~Company”), ofis ~~the~~a ~~Company were~~Nevada ~~transferred from Custodian Ventures~~corporation, ~~LLC~~formed ~~(the~~in ~~“Seller”)~~April 2011 to ~~FiveT~~become ~~Capital~~an ~~Holding~~emerging AGhealthcare ~~(the “Purchaser”). As~~knowledge asolution ~~result,~~company ~~the~~created ~~Purchaser~~to ~~became~~transform anhealth ~~approximately~~and ~~50.2%~~healthcare ~~holder~~by ofdeveloping the ~~voting~~standard ~~rights~~in ofmeasuring ~~the~~clinical ~~issued~~performance and ~~outstanding~~outcomes. The ~~share capital of the~~ Company on adeveloped ~~fully-diluted~~medical ~~basis~~software ofwith ~~the~~tools ~~Company~~ and ~~became~~analytics ~~the~~intended ~~controlling~~to ~~shareholder.~~reduce Incosts ~~connection~~while ~~with~~improving ~~the~~clinical ~~transaction~~performance, ~~David Lazar released~~outcomes, ~~the~~predictive ~~Company~~insight, ~~from~~and ~~all~~evidence-based ~~debts~~best ~~owed~~clinical ~~to him and/or the Seller~~processes.

On August ~~September 23~~10, ~~2020~~2011, holders of a majority of the ~~existing~~Registrant’s ~~director~~outstanding ~~and~~Common Stock voted to amend the Registrant’s Articles ~~officer~~of ~~resigned~~Incorporation ~~immediately.~~to ~~Accordingly,~~increase ~~David~~the ~~Lazar,~~number ~~serving~~of asits aauthorized ~~director~~shares ~~and~~of ancapital ~~officer~~stock from 900,000,000 ~~ceased~~shares to be2,510,000,000 par value $0.001 shares (the ~~Company’s~~“Amendment”) ~~Chief~~of ~~Executive Officer~~which (a) 2,500,000,000 ~~Chief~~shares ~~Financial~~were ~~Officer,~~designated ~~President,~~as ~~Treasurer,~~Common ~~Secretary,~~Stock and ~~Director~~(b) 10,000,000 shares were designated as blank check preferred stock.

OnDuring the ~~November~~period ~~24,~~from ~~2020~~March 22, ~~Quture International~~2013, ~~Inc. amended~~through ~~its~~December ~~articles~~26, ~~of incorporation to change its name to Born~~2019, ~~Inc. (~~the ~~“Name~~Company ~~Change”). The change~~ was ~~made in anticipation of entering into a new line of business operations~~dormant.

~~Also~~On onDecember ~~November~~27, 242019, ~~2020~~Custodian Ventures, ~~the~~LLC, ~~Company~~an ~~amended~~entity controlled ~~its~~by ~~articles~~David ofLazar, ~~incorporation~~was toappointed ~~reverse~~by ~~split~~the ~~its~~Nevada ~~common~~Court ~~stock~~as atthe acustodian ~~rate~~ of 1Bryn. ~~for~~On 1December 31,~~000~~ ~~(the~~2019, ~~“Reverse”)~~Mr. ~~Additionally,~~Lazar became the ~~number~~ ofonly ~~common~~Director ~~shares~~and Officer ~~authorized~~of ~~was~~the ~~reduced from 2~~Company,~~500,000,000~~ toacting ~~500,000,000.~~as Onits ~~December 1~~President, ~~2020~~Treasurer, ~~FINRA declared the Name Change~~ and ~~the Reverse effective~~Secretary.

On ~~November~~September 2410, 2020, the Company ~~amended~~filed ~~its~~a Certificate ~~articles~~of Designation with the State of ~~incorporation~~Nevada todesignating ~~change~~a ~~its~~class ~~name~~of ~~from~~ten ~~Quture~~million ~~International,~~shares ~~Inc.~~of tothe ~~Born~~Company’s Series A preferred stock, ~~Inc~~$.001 par ~~(the~~value ~~“Name~~per ~~Change”).~~share, ~~The~~and ~~change was~~providing ~~made~~for invoting ~~anticipation~~rights ofequal ~~entering~~to ~~into~~250 avotes ~~new~~for ~~line~~each one (1) share of ~~business~~Series ~~operations~~A preferred stock.

7On September 23, 2020, as a result of a private transaction, 10,000,000 shares of Series A Convertible Preferred Stock, $0.001 par value per share (the “Shares”) of the Company were transferred from Custodian Ventures, LLC (the “Seller”) to FiveT Capital Holding AG (the “Purchaser”). As a result, the Purchaser became the holder of 50.2% of the voting rights of the issued and outstanding share capital of the Company on a fully-diluted basis of the Company and became the controlling shareholder. In connection with the transaction, David Lazar released the Company from all debts owed to him and/or the Seller. On the same day, David Lazar, who had been serving as a director and an officer, ceased to be the Company’s Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary, and Director.

~~Also~~On on November 24, 2020, the Company amended its articles of incorporation to change its name to Born, Inc. (the “Name Change”). The change was made in anticipation of entering into a new line of business operations. On the same date, , the Company amended its articles of incorporation to reverse split its common stock at a rate of 1 for 1,000 (the “Reverse”). Additionally, the number of common shares authorized was reduced from 2,500,000,000 to 500,000,000. On December 1, 2020, FINRA declared the Name Change and the Reverse effective.

On February 2, 2021, the Company changed its fiscal year end to December 31.

On February 16, 2021, the Company entered into a share exchange agreement (the “Share Exchange Agreement”) with Alkeon Creators, Inc. (“Alkeon”), a United Kingdom corporation. Under the Share Exchange Agreement, One Hundred Percent (100%) of the ownership interest of Alkeon was exchanged for 406,646,919 shares of common stock of the Company. The former stockholders of Alkeon acquired a majority of the issued and outstanding common stock as a result of the share exchange transaction. The transaction has been accounted for as a recapitalization of the Company, whereby Alkeon is the accounting acquirer.7

~~Immediately~~On February ~~after~~16, ~~completion~~2021, ofthe ~~such~~Company entered into a share exchange on ~~February~~agreement 16(the “Share Exchange Agreement”) with Alkeon Creators, Inc. ~~2021~~(“Alkeon”), a United Kingdom corporation. Under the ~~Company~~Share ~~had~~Exchange aAgreement, ~~total~~One Hundred Percent (100%) of ~~409~~the ownership interest of Alkeon was exchanged for 406,~~353~~646,~~807~~919 shares of common stock of the Company. The former stockholders of Alkeon acquired a majority of the issued and outstanding ~~shares,~~common ~~with~~stock ~~authorized~~as ~~share~~a ~~capital~~result ~~for~~of ~~common~~the share exchange transaction. The transaction has been accounted for as a recapitalization of ~~500~~the Company,~~000,000~~ whereby Alkeon is the accounting acquirer.

~~The~~Immediately after ~~transaction~~completion ~~with~~of ~~Alkeon~~such ~~was~~share ~~voided~~exchange ~~and~~on ~~written off in~~ February 16, 2021., ~~As a result~~ the Company ~~was~~had ~~considered~~ a ~~dormant~~total ~~shell~~of ~~from~~409,353,807 ~~February~~issued ~~2021~~and ~~through~~outstanding ~~July~~shares, ~~2023~~with authorized ~~when~~share itcapital ~~went~~for ~~into~~common ~~custodianship~~share of 500,000,000.

OnThe transaction ~~January~~with ~~14,~~Alkeon ~~2024,~~was voided and written off in February 2021. As a result the ~~Eighth~~Company ~~Judicial~~was ~~District~~considered ~~Court,~~a ~~pursuant~~dormant ~~to Case~~shell ~~A-23-871046B~~from ~~issued~~February 2021 anthrough ~~Order~~July ~~Barring~~2023 ~~Unasserted~~when ~~Claims~~it ~~against~~went ~~Born,~~into ~~Inc~~custodianship.

On January ~~July 16~~14, 2024, the ~~Company~~Eighth ~~changed~~Judicial ~~its~~District ~~name~~ Court, pursuant to ~~Byrn~~Case A-23-871046B issued an Order Barring Unasserted Claims against Born, Inc.

~~The~~On ~~Company~~July ~~has~~16, no2024, ~~operations or revenue as of~~ the ~~date~~Company ofchanged ~~this~~its ~~Report. We~~name ~~are~~to ~~currently~~Byrn ~~in the process of developing a business plan~~Inc. ~~Management~~On ~~intends to explore and identify viable business opportunities~~September ~~within~~4, ~~the U.S.~~2024, ~~including~~the ~~seeking~~Company tochanged ~~acquire~~its aname ~~business~~to inBryn ~~a reverse merger~~Inc.

~~NOTE~~On April 224, –2026 ~~SUMMARY~~MEDO OFHealthcare ~~SIGNIFICANT~~LLC, ~~ACCOUNTING~~an Iowa limited liability company, purchased 10 million shares of the Registrant’s Series A-1 ~~POLICIES~~Preferred Stock from Custodian Ventures LLC, the personal holding company of David Lazar, who was sole director and officer of the Registrant on and prior to April 24, 2026. Pursuant to agreement between David Lazar and MEDO Healthcare, Mr. Lazar resigned on April 24, 2026 from his positions as sole officer and director of the Registrant. Prior to resigning, Mr. Lazar appointed John Leo to serve upon Mr. Lazar’s resignation as sole director and CEO of the Registrant. Mr. Lazar also appointed Arthur Magee, an affiliate of John Leo, to serve upon Mr. Lazar’s resignation as CFO and Secretary of the Registrant.

~~Basis~~The Company has no operations or revenue as of ~~Presentation~~the date of this Report. We are currently in the process of developing a business plan. Management intends to explore and identify viable business opportunities within the U.S., including seeking to acquire a business in a reverse merger.

~~The accompanying financial statements have been~~NOTE ~~prepared~~2 in– ~~accordance~~SUMMARY ~~with~~OF ~~the~~SIGNIFICANT ~~Financial~~ACCOUNTING Accounting Standards Board (“FASB”) “FASB Accounting Standard Codification™” (the “Codification”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States.POLICIES

~~Going~~Basis of ~~Concern~~Presentation

The accompanying financial statements have been prepared ~~assuming~~in accordance with the ~~Company~~ ~~will~~Financial ~~continue~~Accounting asStandards aBoard ~~going~~(“FASB”) “FASB ~~concern,~~Accounting ~~which~~Standard ~~contemplates~~Codification™” (the ~~realization~~“Codification”) ofwhich ~~assets~~is ~~and~~ the ~~satisfaction~~source of ~~liabilities~~authoritative accounting inprinciples recognized by the ~~normal course~~FASB ofto ~~business~~be ~~for~~applied ~~the~~by ~~twelve-month~~nongovernmental ~~period~~entities ~~following~~in the ~~date~~preparation of ~~these~~ financial statements. ~~The Company has incurred significant~~in ~~operating~~conformity ~~losses~~with ~~since~~generally ~~inception.~~accepted Asaccounting ofprinciples ~~September~~(“GAAP”) ~~30,~~in ~~2025~~ the ~~Company~~United ~~had a working capital deficit of $85,168 and had an accumulated deficit of $117,550,693~~States.

~~Because the Company does not expect that existing~~Going operational cash flow will be sufficient to fund presently anticipated operations, this raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing. The Company is currently being funded by David Lazar who is extending interest free demand loans to the Company. Historically, the Company has raised capital through private placements, as an interim measure to finance working capital needs and may continue to raise additional capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to do so until its operations become profitable. Also, the Company has, in the past, paid for consulting services with its common stock to maximize working capital, and intends to continue this practice where feasible.Concern

8The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these financial statements. The Company has incurred significant operating losses since inception. As of March 31, 2026 the Company had a working capital deficit of $34,264 and had an accumulated deficit of $117,593,073.

~~Use~~Because the Company does not expect that existing operational cash flow will be sufficient to fund presently anticipated operations, this raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of ~~Estimates~~financing. The Company is currently being funded by Medo Healthcare, LLC an entity who is extending interest free demand loans to the Company. Historically, the Company has raised capital through private placements, as an interim measure to finance working capital needs and may continue to raise additional capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to do so until its operations become profitable. Also, the Company has, in the past, paid for consulting services with its common stock to maximize working capital, and intends to continue this practice where feasible.

The preparation of financial statements in conformity with US GAAP requires Management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.8

~~Management’s Representation~~ Use of ~~Interim Financial Statements~~Estimates

The preparation ~~accompanying~~of ~~unaudited~~ financial statements ~~have~~ ~~been~~in ~~prepared~~conformity bywith ~~the~~US ~~Company~~GAAP ~~without~~requires ~~audit~~Management ~~pursuant~~ to ~~the~~make ~~rules~~estimates and ~~regulations~~assumptions ofthat affect the reported ~~Securities~~amounts of liabilities and ~~Exchange~~disclosure ~~Commission~~of ~~(“SEC”). Certain~~contingent ~~information~~assets and ~~disclosures~~liabilities ~~normally~~at ~~included~~the indate of the financial statements ~~prepared~~and inthe ~~accordance~~reported amounts ~~with~~of ~~accounting~~revenues ~~principles~~and ~~generally accepted~~expenses induring the ~~United~~reporting ~~States~~period. ~~(“GAAP”)~~The ~~have~~most ~~been~~significant orestimates ~~omitted~~relate asto ~~allowed~~income bytaxes ~~such rules~~ and ~~regulations, and management believes~~contingencies. ~~that~~The ~~the~~Company ~~disclosures~~bases ~~are~~its ~~adequate~~estimates toon ~~make~~historical ~~the~~experience, ~~information~~known ~~presented~~or ~~not~~expected ~~misleading.~~trends ~~These~~and ~~financial~~various ~~statements~~other ~~include~~assumptions ~~all~~that ofare ~~the~~believed ~~adjustments,~~to ~~which~~be inreasonable given the ~~opinion~~quality of ~~management~~information ~~are~~available ~~necessary~~as ~~to a fair presentation~~ of ~~financial~~the ~~position~~date ~~and results~~ of ~~operations.~~these ~~All~~financial ~~such adjustments are of a normal and recurring nature~~statements. ~~Interim~~The results ~~are not necessarily indicative~~ of ~~results~~these ~~for a full year. These financial statements~~assumptions ~~should~~provide bethe ~~read~~basis infor ~~conjunction~~making ~~with~~estimates about the ~~audited~~carrying ~~financial~~amounts ~~statements~~of atassets and asliabilities ofthat ~~December~~are ~~31,~~not ~~2024~~readily ~~filed~~apparent ~~with~~from ~~the~~other sources. ~~SEC~~Actual onresults ~~April~~could ~~15,~~differ ~~2025~~from these estimates.

~~Cash~~Management’s Representation ~~and~~of ~~cash~~Interim ~~equivalents~~Financial Statements

The accompanying unaudited financial statements have been prepared by the Company ~~considers~~without ~~all~~audit ~~highly~~pursuant ~~liquid~~to ~~temporary~~the rules and regulations of ~~cash~~the ~~investments~~Securities and Exchange Commission (“SEC”). Certain information and disclosures normally included in the financial statements prepared in accordance with anaccounting ~~original~~principles ~~maturity~~generally ofaccepted ~~three~~in ~~months~~the United States (“GAAP”) have been or ~~less~~omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to bemake ~~cash~~the ~~equivalents~~information presented not misleading. OnThese ~~September~~financial ~~30,~~statements ~~2025~~include all of the adjustments, which in the opinion of management are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These financial statements should be read in conjunction with the audited financial statements at and as of December 31, ~~2024, the~~2025 ~~Company’s~~filed ~~cash~~with ~~equivalents~~the ~~totaled~~SEC ~~$-0-~~on ~~and~~April ~~$-0-~~2, ~~respectively~~2026.

~~Stock-based~~Cash and ~~Compensation~~cash equivalents

The Company ~~accounts~~considers ~~for~~all ~~stock-based~~highly ~~compensation using~~liquid ~~the~~temporary ~~fair~~cash ~~value~~investments ~~method~~with ~~following~~an ~~the~~original ~~guidance~~maturity ~~outlined in Section 718-10~~ of ~~the~~three ~~FASB~~months ~~Accounting~~or ~~Standards~~less ~~Codification~~to ~~for~~be ~~disclosure about~~cash ~~Stock-Based Compensation~~equivalents. On ~~This~~March ~~section~~31, ~~requires~~2026, aand ~~public~~December ~~entity~~31, to2025, ~~measure~~ the ~~cost~~Company’s ofcash ~~employee~~equivalents ~~services~~totaled ~~received in exchange for an award of equity instruments based on the grant~~$-~~date~~0- ~~fair~~and ~~value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award~~$-0- ~~the requisite service period (usually the vesting period)~~respectively. ~~No compensation cost is recognized for equity instruments for which employees do not render the requisite service.~~

~~Net Loss per Share~~Stock-based Compensation

~~Net~~The Company ~~loss~~accounts ~~per~~for ~~common~~stock-based ~~share~~compensation isusing ~~computed~~the byfair ~~dividing net~~value ~~loss~~method byfollowing the ~~weighted~~guidance ~~average~~outlined ~~common~~in ~~shares~~Section ~~outstanding~~718-10 ~~during~~of the ~~period~~FASB Accounting asStandards ~~defined~~Codification byfor ~~Financial~~disclosure ~~Accounting~~about ~~Standards,~~Stock-Based ~~ASC~~Compensation. ~~Topic~~This ~~260, “Earnings~~section ~~per~~requires ~~Share.”~~a ~~Basic~~public ~~earnings~~entity ~~per~~to ~~common~~measure ~~share~~the cost ~~(“EPS”)~~of ~~calculations~~employee ~~are~~services ~~determined~~received byin ~~dividing~~exchange ~~net~~for ~~income by~~an award of equity instruments based on the ~~weighted~~grant-date ~~average~~fair ~~number~~value of ~~shares~~the ofaward ~~common~~(with limited ~~stock~~exceptions). ~~outstanding~~That ~~during~~cost will be recognized over the ~~year.~~period ~~Diluted~~during ~~earnings~~which ~~per~~an ~~common~~employee ~~share~~is ~~calculations~~required ~~are~~to provide service in exchange ~~determined~~for bythe ~~dividing~~award- ~~net~~the ~~income~~requisite byservice period (usually the ~~weighted~~vesting ~~average~~period). ~~number~~No ofcompensation ~~common~~cost ~~shares~~is ~~and~~recognized ~~dilutive~~for ~~common~~equity ~~share~~instruments ~~equivalents~~for which ~~outstanding~~employees do not render the requisite service.

9Net Loss per Share

~~Recent~~Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by Financial Accounting ~~Pronouncements~~Standards, ASC Topic 260, “Earnings per Share.” Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

~~There is no new accounting guidance that impacts~~Recent ~~the~~Accounting ~~Company’s financial statements.~~Pronouncements

~~NOTE~~There is 3no –new ~~COMMITMENTS~~accounting ~~AND~~guidance ~~CONTINGENCIES~~that impacts the Company’s financial statements.

~~The Company did not have any contractual commitments as of September 30, 2025, and December 31, 2024.~~9

NOTE 3 4 – ~~NOTES~~COMMITMENTS ~~PAYABLE~~AND ~~RELATED PARTY~~CONTINGENCIES

~~Mr. Lazar, the~~ The Company’s ~~Court-appointed custodian~~did isnot ~~considered~~have aany ~~related~~contractual ~~party.~~commitments ~~During~~as ~~the~~of ~~three~~March ~~months ended September 30~~31, ~~2025~~2026, ~~he extended $3,700 in interest-free demand loans to the Company. As of September 30, 2025~~ and December 31, ~~2024, the amount due to Mr~~2025. ~~Lazar were $82,635 and $43,234, respectively.~~

NOTE 4 5 – ~~EQUITY~~NOTES PAYABLE RELATED PARTY

~~Common~~Mr. Lazar, previously the Company’s Court-appointed custodian, and Medo Healthcare, LLC are considered related parties. During the three months ended March 31, 2026, they extended $12,900 and $11,570, respectively in interest-free demand loans to the Company. During the three months ended March 31, 2026, Mr. Lazar received 30,015,577 restricted common shares in return for services performed. Under the terms of this stock issuance, Mr. Lazar agreed to cancel $93,285 of debt. As of March 31, 2026 the balances due to Mr. Lazar and Medo Healthcare were $8,649 and $11,570, respectively for a total of $20,219. As of December 31, 2025 the total related party debt due to Mr. Lazar amounted to $89,035

~~The Company has authorized 500,000,000 shares~~NOTE of5 ~~Common~~– Stock and 10,000,000 shares of Preferred Stock both with a par value of $0.001. As of September 30, 2025, and December 31, 2024, respectively, there were 419,984,423 and 419,984,423 shares of Common Stock issued and outstanding, respectively.EQUITY

~~Series A Preferred Stock~~Common stock

The Company has authorized 500,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock both with a par value of $0.001. As of ~~September~~March 3031, ~~2025~~2026, and December 31, 2024 , respectively, there were 10450,000,000 and ~~Series~~419,984,423 Ashares ~~Preferred~~of ~~Shares~~Common Stock issued and outstanding, ~~which~~respectively. ~~carried~~During ~~super~~the ~~voting~~three ~~rights~~month ofended 21March 31,~~000,000,000~~ ~~common shares~~2026. ~~Each~~Mr ~~share~~Lazar was ofawarded ~~Preferred~~30,015,577 Acommon isshares. ~~convertible~~See ~~into~~Note ~~250~~4. ~~shares~~Notes ofPayable ~~common~~Related ~~stock~~Party.

~~NOTE~~Series A 6Preferred ~~– SUBSEQUENT EVENTS~~Stock

InAs ~~accordance~~of ~~with~~March ~~ASC 855-10~~31, ~~Company~~2026 ~~has~~and ~~performed an~~December ~~evaluation of subsequent events from September 30~~31, 2025, ~~through~~there ~~October~~were 2110, ~~2025~~000,000 ~~the~~Series A ~~date~~Preferred ~~the~~Shares ~~financial~~outstanding ~~statements~~which ~~were~~carried ~~issued. Based~~super onvoting ~~the~~rights ~~evaluation~~of 2,500,000,000 ~~the~~common ~~Company~~shares. ~~did~~Each ~~not~~share ~~identify~~of ~~any~~Preferred ~~subsequent~~A ~~events~~is ~~that~~convertible into ~~would~~250 ~~have~~shares ~~required~~of ~~adjustment~~common ~~or disclosure in the financial statements~~stock.

10NOTE 6 – SUBSEQUENT EVENTS

~~Item~~In 2.accordance ~~Management’s~~with ~~Discussion~~ASC ~~and~~855-10, ~~Analysis~~Company has performed an evaluation of ~~Financial~~subsequent ~~Condition~~events ~~and~~from ~~Results~~March of31, ~~Operations~~2026 through May 19, 2026 the date the financial statements were issued.

~~Organizational~~On ~~History~~April 24, 2026 MEDO Healthcare LLC, an Iowa limited liability company, purchased 10 million shares of the Company’s Series A-1 Preferred Stock from Custodian Ventures LLC, the personal holding company of David Lazar, who was sole director and ~~Overview~~officer of the Company on and prior to April 24, 2026. MEDO Healthcare paid to Custodian Ventures for the shares $175,000 in cash. The principals of MEDO Healthcare plan to change the name of the Company to MEDO Technologies, Inc. to reflect their business plan. MEDO is the acronym for Machine Enhanced Diagnostic Optimization, and the business plan contemplates that the Company will acquire pharmaceuticals distributors with a nation-wide scope, then optimize their business by introducing proprietary AI-based technology to the three major verticals in the pharmaceutical industry: specialty retail, specialty mail-order, and SNF/ALF Institutional.

~~No Current Operations~~10

~~Plan~~Item 2. Management’s Discussion and Analysis of ~~Operation~~Financial Condition and Results of Operations.

~~The Company has no operations from a continuing~~Plan ~~business other than the expenditures related to running the Company and has no revenue from continuing operations as~~ of ~~the date of this Report.~~Operation

~~Management~~The ~~intends~~Company to explore and identify business opportunities within the U.S., including a potential acquisition of an operating entity through a reverse merger, asset purchase or similar transaction. Our Chief Executive Officer has ~~experience in business consulting, although~~ no ~~assurances~~operations ~~can~~from ~~be given that he can identify and implement~~ a ~~viable~~continuing business ~~strategy~~other orthan the ~~that~~expenditures ~~any~~related ~~such strategy will result in profits. Our ability~~ to ~~effectively~~running ~~identify,~~the ~~develop and~~Company ~~implement a viable plan for our business may be hindered by risks~~ and ~~uncertainties~~has ~~which~~no ~~are~~revenue ~~beyond~~from ~~our~~operations ~~control,~~as ~~including~~of ~~without limitation,~~ the ~~continued~~date ~~negative effects~~ of ~~the~~this ~~coronavirus pandemic on the U~~Report.~~S. and global economies.~~

WeOn doApril ~~not~~24, ~~currently~~2026 ~~engage~~MEDO Healthcare inLLC, ~~any~~an ~~business~~Iowa ~~activities that~~limited ~~provide~~liability ~~revenue~~company, orpurchased ~~cash~~10 ~~flow.~~million ~~During~~shares of the ~~next~~Company’s 12Series A-~~month~~1 ~~period~~Preferred weStock ~~anticipate~~from Custodian ~~incurring~~Ventures ~~costs~~LLC, inthe ~~connection~~personal ~~with~~holding ~~investigating~~company of David Lazar, ~~evaluating~~who was sole director and officer of the Company on and prior to April 24, 2026. MEDO Healthcare paid to Custodian Ventures for the shares $175,000 in cash. The principals of MEDO Healthcare plan ~~and~~to ~~negotiating~~change ~~potential~~the ~~business~~name ~~combinations~~of the Company to MEDO Technologies, ~~filing~~Inc. ~~SEC~~to ~~reports~~reflect their business plan. MEDO is the acronym for Machine Enhanced Diagnostic Optimization, and ~~consummating~~the anbusiness ~~acquisition~~plan ofcontemplates anthat ~~operating~~the Company will acquire pharmaceuticals distributors with a nation-wide scope, then optimize their business by introducing proprietary AI-based technology to the three major verticals in the pharmaceutical industry: specialty retail, specialty mail-order, and SNF/ALF Institutional.

~~Given~~Based upon our ~~limited~~current ~~capital resources~~operations, we ~~may~~do ~~consider~~not have sufficient working acapital ~~business~~to ~~combination~~fund ~~with~~our anoperations ~~entity~~over ~~which~~the ~~has~~next ~~recently~~12 ~~commenced~~months. ~~operations,~~If iswe aare ~~developing~~able ~~company~~to close one or more acquisitions, it is ~~otherwise~~likely inwe will need capital as a condition of ~~additional funds~~closing ~~for~~those ~~the~~acquisitions. ~~development~~Because of ~~new~~the ~~products~~uncertainties, orwe ~~services~~cannot orbe ~~expansion~~certain ~~into~~as ~~new~~to ~~markets~~how ormuch iscapital anwe ~~established~~need ~~business~~to ~~experiencing financial~~raise or ~~operating~~the ~~difficulties~~type ~~and~~of issecurities inwe ~~need~~will ofbe ~~additional~~required ~~capital~~to issue. ~~Alternatively,~~If awe ~~business~~are ~~combination~~successful ~~may~~in ~~involve~~acquiring ~~the~~pharmaceuticals ~~acquisition~~distributors ~~of, or~~with ~~merger~~a ~~with~~nationwide scope, anwe ~~entity~~will ~~which~~likely ~~desires~~be ~~access~~required to issue a controlling block of our securities to the ~~U.S.~~shareholders ~~capital~~of ~~markets~~our targets.

AsAdditional issuances of ~~the~~equity ~~date~~or ofconvertible ~~this~~debt ~~Report,~~securities ~~our~~will ~~management has~~result ~~not~~in ~~had~~dilution ~~any~~to ~~discussions~~our ~~with~~current ~~any representative of any other entity regarding a potential business combination~~shareholders. ~~Any~~Further, ~~target~~such ~~business~~securities might ~~that~~have isrights, ~~selected~~preferences, ~~may be financially unstable~~ or inprivileges ~~the~~senior ~~early~~to ~~stages~~our ofCommon ~~development~~Stock. InAdditional ~~such~~financing ~~event,~~may wenot ~~expect to~~ be ~~subject~~available toupon ~~numerous~~acceptable terms, ~~risks~~or ~~inherent~~at inall. ~~the~~If ~~business~~adequate ~~and~~funds ~~operations~~are ofnot aavailable ~~financially~~or ~~unstable~~are ornot ~~early-stage~~available ~~entity.~~on Inacceptable ~~addition~~terms, we may ~~effect~~not abe ~~business~~able ~~combination with~~to antake ~~entity~~advantage inof anprospective new ~~industry~~business ~~characterized~~endeavors ~~by a high level of risk~~ or inopportunities, which ~~our~~could ~~management~~significantly ~~has limited experience,~~ and, ~~although~~materially restrict our ~~management~~ ~~will endeavor to evaluate the risks inherent in a particular target~~ business, ~~there can be no assurance that we will properly ascertain or assess all significant risks~~operations.

~~Our~~We anticipate ~~management anticipates~~ that we will ~~likely only~~incur beoperating ~~able~~losses toin ~~effect~~the ~~one~~next ~~business~~12 ~~combination~~months, ~~due~~principally costs related to our ~~limited~~being ~~capital.~~obligated ~~This~~to ~~lack~~file ofreports with ~~diversification~~the ~~will~~SEC. ~~likely~~Our ~~pose~~prospects amust ~~substantial risk~~be considered in ~~investing~~light inof the ~~Company~~risks, ~~for~~expenses ~~the~~and ~~indefinite~~difficulties ~~future~~frequently ~~because~~encountered itby ~~will~~companies ~~not~~in their ~~permit~~early stage of development. Such risks for us include, but are not limited to, ~~offset~~an ~~potential~~evolving ~~losses~~and ~~from~~unpredictable ~~one~~business ~~venture~~model, orrecognition ~~operating~~of ~~territory~~revenue ~~against~~sources, ~~gains~~and ~~from~~the ~~another~~management of growth. ~~The~~To address these risks, we ~~face~~must, ~~will~~among ~~likely~~other bethings, ~~heightened~~develop, implement, and successfully execute our business and marketing strategy, respond to ~~the~~competitive ~~extent~~developments, weand ~~acquire~~attract, aretain, ~~business~~and ~~operating~~motivate qualified personnel. There can be no assurance that we will be successful in addressing such risks, and the failure to do so could have a ~~single~~material ~~industry~~adverse oreffect on ~~geographical~~our ~~region~~business prospects, financial condition, and results of operations.

We anticipate that the selection of a business combination will be a complex and risk-prone process. Because of general economic conditions, including unfavorable conditions caused by the coronavirus pandemic, rapid technological advances being made in some industries and shortages of available capital, management believes that there are a number of firms seeking business opportunities at this time at discounted rates with which we will compete. We expect that any potentially available business combinations may appear in a variety of different industries or regions and at various stages of development, all of which will likely render the task of comparative investigation and analysis of such business opportunities extremely difficult and complicated. Once we have developed and begun to implement our business plan, management intends to fund our working capital requirements through a combination of our existing funds and future issuances of debt or equity securities. Our working capital requirements are expected to increase in line with the implementation of a business plan and commencement of operations.11

~~Based upon our current operations, we do not have~~Critical ~~sufficient~~Accounting ~~working~~Policies ~~capital~~and to fund our operations over the next 12 months. If we are able to close a reverse merger, it is likely we will need capital as a condition of closing that acquisition. Because of the uncertainties, we cannot be certain as to how much capital we need to raise or the type of securities we will be required to issue. In connection with a reverse merger, we will be required to issue a controlling block of our securities to the target’s shareholders which will be very dilutive.Estimates

~~Additional~~Our management’s ~~issuances~~discussion and analysis of ~~equity~~our orfinancial ~~convertible debt~~condition ~~securities~~and ~~will~~results ~~result~~of inoperations ~~dilution~~is tobased on our ~~current~~unaudited ~~shareholders.~~financial ~~Further~~statements, which ~~such~~have ~~securities~~been ~~might~~prepared ~~have~~in ~~rights,~~accordance ~~preferences~~with U.S. generally accepted accounting principles, or ~~privileges~~“GAAP.” The preparation of ~~senior~~these unaudited financial statements requires us to ~~our~~make ~~Common~~estimates ~~Stock.~~and ~~Additional~~assumptions ~~financing~~that ~~may~~affect ~~not~~the bereported ~~available~~amounts ~~upon~~of ~~acceptable~~assets ~~terms~~and liabilities, disclosure orof contingent assets and liabilities at ~~all.~~the Ifdate ~~adequate~~of ~~funds~~the ~~are~~financial ~~not~~statements, ~~available~~and the reported amounts of revenue and expenses orduring ~~are~~the ~~not~~reported ~~available~~period. onIn ~~acceptable~~accordance ~~terms~~with GAAP, we ~~may~~base ~~not~~our beestimates ~~able~~on tohistorical ~~take~~experience ~~advantage~~and ofon ~~prospective~~various ~~new~~other ~~business~~assumptions that ~~endeavors~~we orbelieve ~~opportunities, which~~are ~~could~~reasonable ~~significantly~~under ~~and~~the ~~materially~~circumstances. ~~restrict~~Actual ~~our~~results ~~business~~may ~~operations~~differ from these estimates under different assumptions or conditions.

11Our significant accounting policies are fully described in Note 2 to our unaudited financial statements appearing elsewhere in this Quarterly Report, and we believe those accounting policies are critical to the process of making significant judgments and estimates in the preparation of our unaudited financial statements.

~~We anticipate that we will incur operating losses~~Off-Balance inSheet the next 12 months, principally costs related to our being obligated to file reports with the SEC. Our prospects must be considered in light of the risks, expenses and difficulties frequently encountered by companies in their early stage of development. Such risks for us include, but are not limited to, an evolving and unpredictable business model, recognition of revenue sources, and the management of growth. To address these risks, we must, among other things, develop, implement, and successfully execute our business and marketing strategy, respond to competitive developments, and attract, retain, and motivate qualified personnel. There can be no assurance that we will be successful in addressing such risks, and the failure to do so could have a material adverse effect on our business prospects, financial condition, and results of operations.Arrangements

~~Critical Accounting Policies and Estimates~~None.

~~Our management’s discussion and analysis~~Item ~~of our financial condition and results of operations is based on our unaudited financial statements, which have been prepared in accordance with U~~3.S. ~~generally~~Quantitative ~~accepted~~And ~~accounting~~Qualitative ~~principles,~~Disclosures orAbout ~~“GAAP.”~~Market The preparation of these unaudited financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reported periodRisk. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

~~Our significant accounting policies are fully~~As ~~described~~a insmaller ~~Note~~reporting ~~2 to our unaudited financial statements appearing elsewhere in this Quarterly Report~~company, ~~and~~ we ~~believe those accounting policies~~ are ~~critical~~not required to ~~the~~provide ~~process of making significant judgments and estimates in~~ the ~~preparation~~information ofcalled ~~our~~for ~~unaudited~~by ~~financial~~this ~~statements~~Item.

~~Off-Balance~~Item 4. ~~Sheet~~Controls ~~Arrangements~~and Procedures.

~~None~~Evaluation of Disclosure Controls and Procedures.

~~Item~~Our 3management is responsible for establishing and maintaining a system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the Commission’s rules and forms. ~~Quantitative~~Disclosure ~~And~~controls ~~Qualitative~~and ~~Disclosures~~procedures include, ~~About~~without ~~Market~~limitation, ~~Risk~~controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

~~As a smaller reporting company, we are not required to provide the information called for by this Item.~~12

~~Item~~Our 4.management ~~Controls~~assessed the effectiveness of our disclosure controls and ~~Procedures.~~procedures based on the parameters set forth above and has concluded that as of March 31, 2026, our disclosure controls and procedures have the following material weaknesses:

~~Evaluation~~● The Company does not have sufficient segregation of ~~Disclosure~~duties ~~Controls~~within accounting functions due to only having two officers and ~~Procedures~~limited resources. ● The Company does not have an independent board of directors or an audit committee. ● The Company does not have written documentation of our internal control policies and procedures. ● The greater portion of the Company’s financial reporting is carried out by a financial consultant.

~~Our management is responsible for establishing~~We ~~and~~plan ~~maintaining a system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed~~ to ~~ensure~~rectify ~~that~~these ~~information~~weaknesses ~~required to be disclosed~~ by usimplementing inan ~~the~~independent ~~reports~~board ~~that~~of ~~we file or submit under the Exchange Act is recorded~~directors, ~~processed,~~establishing ~~summarized,~~written ~~and~~policies ~~reported, within the time periods specified in the Commission’s rules~~ and ~~forms.~~procedures ~~Disclosure~~for ~~controls~~our ~~and~~internal ~~procedures~~control ~~include,~~of ~~without~~financial ~~limitation~~reporting, ~~controls~~ and ~~procedures~~hiring ~~designed~~additional toaccounting ~~ensure~~personnel ~~that~~at ~~information~~such ~~required~~time toas bewe ~~disclosed by~~complete ana ~~issuer~~reverse ~~in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management,~~merger ~~including its principal executive officer~~ or ~~officers and principal financial officer or officers, or persons performing~~ similar ~~functions, as~~business ~~appropriate to allow timely decisions regarding required disclosure~~acquisition. ~~Management has concluded that our disclosure controls were not effective as of September 30, 2025.~~

~~Management’s~~Changes in ~~Report on~~ Internal Control over Financial Reporting.

~~Our~~There ~~management~~have isbeen ~~responsible~~no ~~for~~change ~~establishing and~~in ~~maintaining~~our ~~adequate~~ internal control over financial reporting ~~as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act.~~ ~~Our~~during ~~internal control over financial reporting is designed to provide reasonable assurance regarding~~ the ~~reliability~~three ofmonths ~~financial~~ended ~~reporting and~~March ~~the~~31, ~~preparation~~2026 ofthat ~~financial~~has ~~statements~~materially ~~for~~affected, ~~external~~or ~~purposes~~is inreasonably ~~accordance~~likely ~~with~~to ~~generally~~materially ~~accepted~~affect, ~~accounting~~our ~~principles. Our~~ internal control over financial reporting ~~includes those policies and procedures that:~~.

● pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; ● provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and ● provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.13

12PART II – OTHER INFORMATION

~~Because of its inherent limitations, internal~~Item ~~control over financial reporting may not prevent or detect misstatements~~1. ~~Also,~~Legal projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorateProceedings.

~~Our~~The Company ~~management~~may ~~assessed~~be ~~the~~involved ~~effectiveness~~in ofcertain ~~our internal~~legal ~~control~~proceedings ~~over~~that ~~financial~~arise ~~reporting~~from ~~based~~time onto time in the ~~parameters~~ordinary ~~set~~course ~~forth~~of ~~above~~its ~~and~~business. ~~has~~Legal ~~concluded~~expenses associated ~~that~~with asany ofcontingency ~~September~~are ~~30,~~expensed ~~2025,~~as ~~our internal~~incurred. ~~control~~The ~~over~~Company’s ~~financial~~officers ~~reporting~~and ~~was~~directors are not ~~effective~~aware toof ~~provide~~any ~~reasonable~~threatened or ~~assurance~~pending ~~regarding~~litigation ~~the~~to ~~reliability~~which ofthe ~~financial~~Company ~~reporting and~~is ~~the~~a ~~preparation~~party ofor ~~financial~~which ~~statements~~any ~~for~~of ~~external~~its ~~purposes~~property inis ~~accordance~~the ~~with~~subject ~~U.S.~~and ~~generally~~which ~~accepted~~would ~~accounting~~have ~~principles~~any asmaterial, aadverse ~~result~~effect ofon the ~~following material weaknesses:~~Company.

~~● The Company does not have sufficient segregation of duties within accounting functions due to only having one officer and limited resources~~Item 1A. ●Risk ~~The Company does not have an independent board of directors or an audit committee~~Factors. ~~● The Company does not have written documentation of our internal control policies and procedures. ● All of the Company’s financial reporting is carried out by a financial consultant.~~

We ~~plan to rectify these weaknesses by implementing~~ anare ~~independent~~a ~~board~~smaller ofreporting ~~directors,~~company ~~establishing written policies~~ and ~~procedures~~not ~~for~~required ~~our~~to ~~internal~~include ~~control~~risk offactor ~~financial reporting, and hiring additional accounting personnel at such time as we complete a reverse merger or similar business acquisition~~disclosures.

~~Changes~~Item 2. inUnregistered ~~Internal~~Sales ~~Control~~of ~~over~~Equity ~~Financial Reporting~~Securities and Use Of Proceeds.

There have been no change in our internal control over financial reporting during the nine months ended September 30, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reportingNone.

13Item 3. Defaults Upon Senior Securities.

~~PART II – OTHER INFORMATION~~None.

Item 1 4. ~~Legal~~Mine ~~Proceedings~~Safety Disclosures.

~~The Company may be involved in certain legal proceedings~~Not ~~that arise from time to time in the ordinary course of its business~~applicable. Legal expenses associated with any contingency are expensed as incurred. The Company’s officers and directors are not aware of any threatened or pending litigation to which the Company is a party or which any of its property is the subject and which would have any material, adverse effect on the Company.

Item 1A 5. ~~Risk~~Other ~~Factors~~Information.

WeDuring ~~are~~the aquarter ~~smaller~~ended ~~reporting~~March ~~company~~31, ~~and~~2026, ~~not~~no ~~required~~director toor ~~include~~officer ~~risk~~adopted or terminated any Rule 10b5-1 trading ~~factor~~arrangement ~~disclosures~~or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

~~Item 2. Unregistered Sales of Equity Securities and Use Of Proceeds.~~14

~~None~~Item 6. Exhibits.

~~Item~~The following 3.exhibits ~~Defaults~~are ~~Upon~~included ~~Senior~~as ~~Securities.~~part of this report:

None.

Exhibit		Incorporated by Reference
Number	Exhibit Description	Form	Exhibit	Filing Date
3.1	Articles of Incorporation and Amendments, as filed with the Nevada Secretary of State.	SB-2	3.1	6/8/2007

3.2-a	Certificates of Amendment	10-K	3.2	7/21/2020

3.2-b	Certificate of Correctiton*

3.3	Motion for Custodianship	10-K	3.3	7/21/2020

3.4	Certificate of Reinstatement	10-K	3.4	7/21/2020

3.5	Bylaws	SB-2	3.2	6/8/2007

31*	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer and Chief Financial Officer.

32*	Rule 1350 Certifications of Chief Executive Officer and Chief Financial Officer.

101.INS*	XBRL Instance Document.

101.SCH*	XBRL Taxonomy Extension Schema Document.

101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.

101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.

104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

~~Item~~* 4.Filed ~~Mine Safety Disclosures~~herewith.

~~Not applicable.~~15

~~Item 5. Other Information.~~SIGNATURES

~~None~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BRYN, INC.

Dated: May 19, 2026	By:	/s/ John Leo
		John Leo
		Chief Executive Officer and Principal Executive Officer,

Item 6. Exhibits.

Dated: May 19, 2026	By:	/s/ Arthur Magee
		Arthur Magee
		Chief Financial Officer and Principal Financial and Accounting Officer,

~~The~~to the ~~following~~requirements ~~exhibits~~of ~~are~~the ~~included~~Securities asExchange ~~part~~Act of 1934, this report: has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Exhibit		Incorporated by Reference
Number	Exhibit Description	Form	Exhibit	Filing Date
3.1	Articles of Incorporation and Amendments, as filed with the Nevada Secretary of State.	SB-2	3.1	6/8/2007
3.2	Certificates of Amendment	10-K	3.2	7/21/2020
3.3	Motion for Custodianship	10-K	3.3	7/21/2020
3.4	Certificate of Reinstatement	10-K	3.4	7/21/2020
3.5	Bylaws	SB-2	3.2	6/8/2007
31*	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer and Chief Financial Officer.
32*	Rule 1350 Certifications of Chief Executive Officer and Chief Financial Officer.
101.INS*	XBRL Instance Document.
101.SCH*	XBRL Taxonomy Extension Schema Document.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* Filed herewith. 0001397795 false Q1 --12-31 0001397795 2026-01-01 2026-03-31 0001397795 2026-05-19 0001397795 2026-03-31 0001397795 2025-12-31 0001397795 us-gaap:RelatedPartyMember 2026-03-31 0001397795 us-gaap:RelatedPartyMember 2025-12-31 0001397795 2025-01-01 2025-03-31 0001397795 us-gaap:PreferredStockMember 2024-12-31 0001397795 us-gaap:CommonStockMember 2024-12-31 0001397795 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001397795 us-gaap:RetainedEarningsMember 2024-12-31 0001397795 2024-12-31 0001397795 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001397795 us-gaap:PreferredStockMember 2025-03-31 0001397795 us-gaap:CommonStockMember 2025-03-31 0001397795 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001397795 us-gaap:RetainedEarningsMember 2025-03-31 0001397795 2025-03-31 0001397795 us-gaap:PreferredStockMember 2025-12-31 0001397795 us-gaap:CommonStockMember 2025-12-31 0001397795 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001397795 us-gaap:RetainedEarningsMember 2025-12-31 0001397795 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001397795 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001397795 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001397795 us-gaap:PreferredStockMember 2026-03-31 0001397795 us-gaap:CommonStockMember 2026-03-31 0001397795 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001397795 us-gaap:RetainedEarningsMember 2026-03-31 0001397795 srt:MinimumMember 2011-08-10 0001397795 srt:MaximumMember 2011-08-10 0001397795 ck0001397795:RegistrantsArticlesOfIncorporationMember us-gaap:CommonStockMember 2011-08-10 0001397795 us-gaap:PreferredStockMember 2011-08-10 0001397795 ck0001397795:MrLazarMember 2020-04-05 0001397795 ck0001397795:MrLazarMember us-gaap:PreferredStockMember 2020-04-05 0001397795 us-gaap:SeriesAPreferredStockMember 2020-09-10 0001397795 ck0001397795:SeriesAConvertiblePreferredStockMember 2020-09-23 0001397795 2020-09-23 2020-09-23 0001397795 us-gaap:CommonStockMember 2020-11-24 2020-11-24 0001397795 srt:MinimumMember 2020-11-24 0001397795 srt:MaximumMember 2020-11-24 0001397795 ck0001397795:AlkeonCreatorsIncMember 2021-02-16 0001397795 2021-02-16 2021-02-16 0001397795 ck0001397795:ByrnIncMember us-gaap:CommonStockMember 2021-02-16 0001397795 2026-04-24 2026-04-24 0001397795 ck0001397795:MrLazarMember 2026-01-01 2026-03-31 0001397795 ck0001397795:MedoHealthcareLLCMember 2026-01-01 2026-03-31 0001397795 ck0001397795:MrLazarMember 2026-03-31 0001397795 ck0001397795:MedoHealthcareLLCMember 2026-03-31 0001397795 us-gaap:SeriesAPreferredStockMember 2026-03-31 0001397795 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001397795 us-gaap:SubsequentEventMember 2026-04-24 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BYRN, INC.
Dated: October 21, 2025	By:	/s/ David Lazar
		David Lazar
		Chief Executive Officer and Chief Financial Officer Principal Executive Officer, Principal Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

0001397795 false Q3 --12-31 0001397795 2025-01-01 2025-09-30 0001397795 2025-10-21 0001397795 2025-09-30 0001397795 2024-12-31 0001397795 us-gaap:RelatedPartyMember 2025-09-30 0001397795 us-gaap:RelatedPartyMember 2024-12-31 0001397795 2025-07-01 2025-09-30 0001397795 2024-07-01 2024-09-30 0001397795 2024-01-01 2024-09-30 0001397795 us-gaap:PreferredStockMember 2023-12-31 0001397795 us-gaap:CommonStockMember 2023-12-31 0001397795 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001397795 us-gaap:RetainedEarningsMember 2023-12-31 0001397795 2023-12-31 0001397795 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001397795 2024-01-01 2024-03-31 0001397795 us-gaap:PreferredStockMember 2024-03-31 0001397795 us-gaap:CommonStockMember 2024-03-31 0001397795 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001397795 us-gaap:RetainedEarningsMember 2024-03-31 0001397795 2024-03-31 0001397795 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001397795 2024-04-01 2024-06-30 0001397795 us-gaap:PreferredStockMember 2024-06-30 0001397795 us-gaap:CommonStockMember 2024-06-30 0001397795 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001397795 us-gaap:RetainedEarningsMember 2024-06-30 0001397795 2024-06-30 0001397795 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001397795 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001397795 us-gaap:PreferredStockMember 2024-09-30 0001397795 us-gaap:CommonStockMember 2024-09-30 0001397795 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001397795 us-gaap:RetainedEarningsMember 2024-09-30 0001397795 2024-09-30 0001397795 us-gaap:PreferredStockMember 2024-12-31 0001397795 us-gaap:CommonStockMember 2024-12-31 0001397795 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001397795 us-gaap:RetainedEarningsMember 2024-12-31 0001397795 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001397795 2025-01-01 2025-03-31 0001397795 us-gaap:PreferredStockMember 2025-03-31 0001397795 us-gaap:CommonStockMember 2025-03-31 0001397795 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001397795 us-gaap:RetainedEarningsMember 2025-03-31 0001397795 2025-03-31 0001397795 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001397795 2025-04-01 2025-06-30 0001397795 us-gaap:PreferredStockMember 2025-06-30 0001397795 us-gaap:CommonStockMember 2025-06-30 0001397795 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001397795 us-gaap:RetainedEarningsMember 2025-06-30 0001397795 2025-06-30 0001397795 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001397795 us-gaap:PreferredStockMember 2025-09-30 0001397795 us-gaap:CommonStockMember 2025-09-30 0001397795 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001397795 us-gaap:RetainedEarningsMember 2025-09-30 0001397795 srt:MinimumMember 2011-08-10 0001397795 srt:MaximumMember 2011-08-10 0001397795 us-gaap:CommonStockMember 2011-08-10 0001397795 us-gaap:PreferredStockMember 2011-08-10 0001397795 ck0001397795:MrLazarMember 2020-04-05 0001397795 ck0001397795:MrLazarMember us-gaap:PreferredStockMember 2020-04-05 0001397795 ck0001397795:MrLazarMember us-gaap:SeriesAPreferredStockMember 2020-09-10 0001397795 us-gaap:SeriesAPreferredStockMember 2020-09-10 0001397795 ck0001397795:SeriesAConvertiblePreferredStockMember 2020-09-23 0001397795 2020-09-23 2020-09-23 0001397795 us-gaap:CommonStockMember 2020-11-24 2020-11-24 0001397795 srt:MinimumMember 2020-11-24 0001397795 srt:MaximumMember 2020-11-24 0001397795 ck0001397795:AlkeonCreatorsIncMember 2021-02-16 0001397795 2021-02-16 2021-02-16 0001397795 us-gaap:CommonStockMember 2021-02-16 0001397795 ck0001397795:MrLazarMember 2025-07-01 2025-09-30 0001397795 ck0001397795:MrLazarMember 2025-09-30 0001397795 ck0001397795:MrLazarMember 2024-12-31 0001397795 us-gaap:SeriesAPreferredStockMember 2025-09-30 0001397795 us-gaap:SeriesAPreferredStockMember 2024-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Filing Compare · Bryn Inc.